LIGAND PHARMACEUTICALS INC (LGND)
NASDAQ • Healthcare
Last close at August 11, 2026 at 20:00 UTC
Fundamentals Charts
About LIGAND PHARMACEUTICALS INC
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) is a biotechnology company that licenses and supports a portfolio of marketed medicines and formulation technology for pharmaceutical companies worldwide. Its business spans oncology, vaccines, central nervous system, anti-infective, cardiovascular, and bone-health products, and generated $268.1 million of revenue in FY2025.
Analyst Ratings
Fundamentals & Financials
TTM is calculated as the sum of the four most recently completed quarters. This is a standard approach when monthly or real-time data is not available.
Income Statement
Balance Sheet
Financial Highlights
Dividends History
Split History
Earnings Calendar
Technical Indicators
LIGAND PHARMACEUTICALS INC's Technical Indicators Summary
LGND is technically mixed with limited trend strength and offsetting moving-average signals. ADX is low, implying a lack of directional conviction, and momentum indicators sit near neutral while MACD is modestly positive. The near-term averages slightly exceed the current price, yet medium-to-long-term moving averages remain well below, indicating longer-horizon support beneath the market. Volatility is moderate and the pivot lies close to the quote, so intraday action is subdued, while OBV shows divergence relative to price. Technical takeaway: Neutral — low trend strength and split moving averages produce a balanced technical profile.
| Indicator | Value |
|---|---|
RSI (14) | 49.64 |
Stochastic %K (14, 3, 3) | 26.72 |
CCI (20) | -92.36 |
WPR (14) | -70.00 |
Momentum (10) | 5.88 |
MFI | 30.32 |
MACD Level (12, 26) | 0.82 |
Bollinger Bands | $286.09 - $307.80 |
ATR (14) | $11.70 (3.98%) |
ADX (14) | 13.73 |
OBV | 7,271,904 |
Classic Pivot Point | $292.23 |
Fibonacci Pivot Point | $292.23 |
Simple Moving Averages | $224.72 - $296.94(5 indicators) |
Exponential Moving Averages | $232.38 - $295.87(5 indicators) |
Get premium market insights delivered directly to your inbox.